Use of CESI,Simplified CDAI and CRP in Evaluating Extent of Lesion and Disease Activity in Small Bowel Crohn's Disease

YANG Li,Zhizheng Ge,GAO Yunjie,Xiaobo Li,DAI Jun,ZHANG Yao,XUE Hanbing,ZHAO Yunjia
DOI: https://doi.org/10.3969/j.issn.1008-7125.2012.06.004
2012-01-01
Abstract:Background: Small bowel Crohn's disease(CD) is a chronic relapsing disease.Up to date,data on the value of capsule endoscopy scoring index(CESI),simplified CDAI and CRP in assessing the extent of lesion and disease activity in small bowel CD are limited.Aims: To assess the value of CESI,simplified CDAI and CRP in evaluating the extent of lesion and disease activity in small bowel CD.Methods: Fifty-eight consecutive small bowel CD patients who had undergone capsule endoscopy were enrolled.The relationship between simplified CDAI,CRP and the extent of lesion was assessed,and the correlations between patients' clinical characteristics and CESI were evaluated.Sensitivity,specificity,positive predictive value and negative predictive value,as well as overall accuracy of simplified CDAI and CRP for predicting disease activity by capsule endoscopy were determined.After treatment,11 patients underwent the second capsule endoscopy.Correlations between changes of CESI and changes of simplified CDAI and CRP were analyzed.Results: No significant difference in simplified CDAI and CRP was found between patients with different extent of lesion in small bowel CD(P>0.05).Clinical characteristics of small bowel CD were not correlated with CESI.Sensitivity,specificity,positive predictive value and negative predictive value,as well as overall accuracy of simplified CDAI and CRP for predicting disease activity by capsule endoscopy were low.After treatment,changes of CESI were not correlated with those of simplified CDAI and CRP(P>0.05).Conclusions: Simplifed CDAI and CRP can not be used as surrogate markers for the assessment of extent of lesion and disease activity in small bowel CD diagnosed by capsule endoscopy.The changes of clinical disease activity and biological markers are poorly correlated with objective capsule endoscopic improvement during small bowel CD therapy.
What problem does this paper attempt to address?